```html

Fungal Endocarditis – A Complete Medical Guide

Overview

Fungal endocarditis (FE) is a rare but life‑threatening infection of the inner lining of the heart chambers and valves (the endocardium) caused by fungi rather than bacteria. It accounts for approximately 2–5% of all infective endocarditis cases in the United States, although the exact prevalence varies by region and patient population.<sup>CDC</sup> The condition most often involves the left‑sided heart valves (mitral or aortic), but right‑sided involvement can occur, especially in patients with central venous catheters or intravenous drug use.

Who is affected? FE primarily occurs in individuals with weakened immune systems or those who have had prolonged exposure to medical devices. The highest‑risk groups include:

• Patients with prolonged broad‑spectrum antibiotic therapy
• Individuals with indwelling catheters, prosthetic heart valves, or cardiac implantable electronic devices (CIEDs)
• Recipients of solid‑organ or hematopoietic stem‑cell transplants
• People with neutropenia or other severe immunosuppression (e.g., chemotherapy, high‑dose steroids)
• Intravenous drug users (IVDU) – though bacterial endocarditis is more common, fungi such as Candida and Aspergillus have been reported.

Because FE is uncommon, many clinicians may not suspect it early, which contributes to delayed diagnosis and higher mortality (reported 30‑day mortality rates of 30–50%).<sup>Mayo Clinic</sup>

Symptoms

Symptoms of fungal endocarditis often develop slowly and can mimic bacterial endocarditis or other cardiac conditions. A complete list with brief descriptions follows:

• Fever and chills – Persistent low‑grade or high‑grade fever lasting weeks.
• Night sweats – Profuse sweating unrelated to ambient temperature.
• Fatigue and malaise – Generalized weakness that limits daily activities.
• Weight loss – Unintentional loss of >5% body weight over a month.
• Heart murmur – New or changing murmur caused by valve destruction or vegetation.
• Chest pain – May be pleuritic or due to embolic infarction of the myocardium.
• Shortness of breath (dyspnea) – Especially on exertion, reflecting heart failure.
• Peripheral emboli – Sudden loss of limb function, visual changes, or abdominal pain from fungal clumps breaking off and traveling through the bloodstream.
• Janeway lesions – Non‑tender, erythematous macules on palms or soles.
• Osler nodes – Tender nodules on finger or toe pads.
• Splinter hemorrhages – Small linear bleeding under the nails.
• Neurologic deficits – Stroke‑like symptoms from cerebral emboli.
• Renal dysfunction – Hematuria or rising creatinine due to embolic renal infarcts.

Because symptoms are nonspecific, a high index of suspicion is essential, especially in high‑risk patients.

Causes and Risk Factors

Fungal endocarditis is most commonly caused by two genera:

Candida species

• Candida albicans (≈50% of cases)
• Candida tropicalis, glabrata, parapsilosis (less common)

Aspergillus species

• Aspergillus fumigatus (most frequent Aspergillus agent)
• Other molds (e.g., Fusarium, Histoplasma) are rare but reported.

Key mechanisms that allow fungi to invade heart tissue include:

• Hematogenous spread from a primary source (e.g., candidemia from a central line).
• Direct seeding during cardiac surgery or valve replacement.
• Biofilm formation on prosthetic material, which protects fungi from host immunity and antifungal drugs.

Major risk factors

• Prolonged (>10 days) use of broad‑spectrum antibiotics – disrupts normal bacterial flora and promotes fungal overgrowth.
• Indwelling intravascular devices (central venous catheters, hemodialysis catheters).
• Cardiac prostheses (mechanical or bioprosthetic valves, pacemaker leads).
• Immunosuppression: chemotherapy, steroids ≥20 mg/day for ≥2 weeks, HIV/AIDS with CD4 <200 cells/µL.
• Neutropenia (ANC <500 cells/µL) lasting >7 days.
• History of prior bacterial endocarditis.
• Recent gastrointestinal surgery or severe mucosal injury (provides portal of entry).

Diagnosis

Diagnosing fungal endocarditis requires a combination of clinical suspicion, imaging, microbiology, and sometimes histopathology.

1. Blood Cultures

• At least three sets of blood cultures drawn from separate sites over 24 hours.
• Fungal organisms may take 48–72 hours to grow; prolonged incubation (up to 7 days) improves yield.
• Approximately 50–70% of cases have positive blood cultures; negative cultures do not exclude FE.

2. Imaging Studies

• Transthoracic echocardiography (TTE) – First‑line; detects large vegetations but may miss small lesions.
• Transesophageal echocardiography (TEE) – Sensitivity >90% for prosthetic‑valve endocarditis; preferred when TTE is inconclusive.
• Cardiac CT or MRI – Helpful for assessing peri‑valvular abscesses or mycotic aneurysms.

3. Serologic & Molecular Tests

• β‑D‑glucan assay – Elevated in invasive fungal infections, including FE, but not specific.
• Galactomannan assay – Useful for detecting Aspergillus infections, especially in neutropenic patients.
• Polymerase chain reaction (PCR) – Can identify fungal DNA directly from blood or valve tissue, increasing diagnostic yield.

4. Tissue Diagnosis

• During cardiac surgery, excised valve tissue is sent for histopathology (Gomori methenamine silver stain) and culture.
• Pathology confirms fungal hyphae or yeast forms and helps differentiate species.

5. Diagnostic Criteria

The modified Duke criteria for infective endocarditis can be applied, but clinicians often need to add “fungal” as a microbiologic major criterion when cultures grow yeasts or molds.

Treatment Options

Effective management combines aggressive antifungal therapy, possible surgical intervention, and mitigation of underlying risk factors.

1. Antifungal Medications

Drug	Typical Regimen	Key Points
Amphotericin B (liposomal)	5 mg/kg IV daily*	Broad‑spectrum, gold‑standard for Candida and Aspergillus; watch for nephrotoxicity.
Echinocandins (Caspofungin, Micafungin, Anidulafungin)	Caspofungin 70 mg loading, then 50 mg IV daily	Effective against most Candida species; limited activity against Aspergillus.
Azoles (Voriconazole, Posaconazole, Fluconazole)	Voriconazole 6 mg/kg IV q12h 2 days, then 4 mg/kg q12h	First‑line for Aspergillus; drug‑interaction monitoring essential.
Combination therapy	Amphotericin B + Flucytosine (25 mg/kg PO/IV q6h)	Often used for prosthetic‑valve infection; improves sterilization.

*Liposomal formulation preferred for reduced renal toxicity (e.g., AmBisome).

Typical treatment duration is **6‑8 weeks** of intravenous therapy, followed by **oral suppressive therapy** (e.g., fluconazole 400 mg daily) for several months, especially when prosthetic material remains.

2. Surgical Intervention

• Valve replacement or repair – Indicated in >50% of cases due to large vegetations, heart failure, or uncontrolled infection.
• Removal of infected devices – Extracting central lines, pacemaker leads, or prosthetic valves is critical for cure.
• Early surgery (within 7–10 days of diagnosis) improves survival (mortality ↓ from 55% to ≈35%).<sup>Cleveland Clinic</sup>

3. Supportive Care & Lifestyle Adjustments

• Optimizing renal and hepatic function to tolerate antifungals.
• Close monitoring of drug levels for azoles (e.g., voriconazole trough 1‑5 µg/mL).
• Management of heart failure symptoms (diuretics, ACE inhibitors as indicated).
• Nutrition support and physiologic rehabilitation during prolonged hospitalization.

Living with Fungal Endocarditis

Even after successful treatment, patients often face a long recovery period. Practical tips for daily management include:

• Medication adherence – Use pill organizers, set alarms, and keep a medication diary.
• Regular follow‑up – Cardiology visits every 1–3 months for echocardiograms; infectious disease clinic for drug monitoring.
• Vaccinations – Annual influenza and COVID‑19 vaccines are safe and help prevent secondary infections.
• Infection‑prevention hygiene – Strict hand washing, avoid crowded sick‑person areas, and promptly treat any skin breaks.
• Dental care – Prophylactic antibiotics are not routinely recommended for fungal organisms, but excellent oral hygiene reduces bacterial co‑infection risk.
• Physical activity – Low‑impact aerobic exercise (walking, stationary bike) as tolerated; avoid heavy lifting that raises intrathoracic pressure.
• Psychosocial support – Seek counseling or support groups for chronic illness coping.

Prevention

Because most cases arise from healthcare‑associated exposures, prevention focuses on minimizing iatrogenic risk.

1. Catheter stewardship – Remove central lines as soon as clinically feasible; use antiseptic‑coated catheters when prolonged use is unavoidable.
2. Antifungal prophylaxis – Consider in high‑risk patients (e.g., neutropenic stem‑cell transplant recipients) per IDSA guidelines.<sup>IDSA</sup>
3. Antibiotic stewardship – Limit broad‑spectrum antibiotics to appropriate indications to reduce fungal overgrowth.
4. Surgical asepsis – Ensure strict sterile technique during valve surgeries and device implantations.
5. Screening for candidemia – In patients with persistent fever and risk factors, obtain early blood cultures and β‑D‑glucan testing.
6. Patient education – Teach patients with prosthetic valves or indwelling devices to recognize early signs of infection.

Complications

If fungal endocarditis is not promptly treated, several serious complications can develop:

• Heart failure – Due to valvular destruction or severe regurgitation.
• Systemic embolization – Cerebral stroke, splenic or renal infarcts, limb ischemia.
• Mycotic aneurysm – Infectious dilation of arterial walls, most common in cerebral vessels.
• Abscess formation – Perivalvular or myocardial abscesses that may require surgical drainage.
• Persistent fungemia – Leads to multi‑organ sepsis and high mortality.
• Prosthetic valve dysfunction – Necessitating re‑operation.
• Renal failure – From embolic injury or drug nephrotoxicity.

When to Seek Emergency Care

---

References:

• Mayo Clinic. Infective Endocarditis. https://www.mayoclinic.org
• CDC. Endocarditis – Clinical Guidelines. https://www.cdc.gov
• NIH National Institute of Allergy and Infectious Diseases. Fungal Endocarditis. https://www.niaid.nih.gov
• World Health Organization. Antimicrobial Resistance Fact Sheet. https://www.who.int
• Cleveland Clinic. Valve Surgery Outcomes. https://my.clevelandclinic.org
• IDSA Clinical Practice Guideline for the Management of Candidiasis. https://www.idsociety.org

```